Skip to main content

Market Overview

UPDATE: Sterne Agee Resumes Charles River Laboratories at Buy on Multiple Positive Factors


In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on Charles River Laboratories (NYSE: CRL) with a Buy rating and $56.00 price target.

In the report, Sterne Agee noted, “In our view, CRL can be characterized as a dominant player within businesses that possess high barriers to entry. With innovative product and service offerings offered at competitive prices, we believe large biopharmaceutical companies seeking to variable-ize cost structures will look to CRL as a provider of choice. We are re-initiating coverage of CRL with a Buy rating and $56 price target.”

Charles River Laboratories closed on Tuesday at $42.27.

Latest Ratings for CRL

Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Truist SecuritiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings


Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Initiation Analyst Ratings

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at